CONCORDBIO Q1 FY27 Guidance vs Delivery (CONCORDBIO Management Mirror)

Q1 FY27 Revenue Reported at 26.2% YoY Growth; FY27 Guidance Reaffirmed to Exceed Historical 18-20% Rate

In the Dec'25 Qtr concall, management expected overall FY26 revenue to remain below historical averages while targeting normalized momentum for FY27 and a 25% CAGR over 3 to 5 years. In the Mar'26 Qtr concall, FY26 revenue was reported at a 12% YoY decline, and management initiated FY27 guidance, expecting full-year revenue growth to be slightly better than the historical growth rate of approximately 18% to 20%. In the latest Jun'26 Qtr concall, management reaffirmed this outlook, expecting the FY27 growth rate to be better than historic growth rates. Quarterly Financial Results for the Jun'26 Qtr report revenue of INR 25,749 Lakh (26.2% YoY growth). Furthermore, management reaffirmed their 5 to 6-year horizon target of reaching close to INR 3,000 crores in revenue, driven by INR 600 to 700 crores from formulations and INR 2,200 crores from the API segment.